You are not currently logged in.
Access JSTOR through your library or other institution:
Neutralization of Tumor Necrosis Factor (TNF) by Antibody but Not TNF Receptor Fusion Molecule Exacerbates Chronic Murine Tuberculosis
Hillarie L. Plessner, P. Ling Lin, Tadahiko Kohno, James S. Louie, Denise Kirschner, John Chan and JoAnne L. Flynn
The Journal of Infectious Diseases
Vol. 195, No. 11 (Jun. 1, 2007), pp. 1643-1650
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30086153
Page Count: 8
You can always find the topics here!Topics: Infections, Mycobacterium tuberculosis, Mice, Antibodies, Lungs, Granuloma, Tuberculosis, Molecules, T lymphocytes, Tumor necrosis factors
Were these topics helpful?See somethings inaccurate? Let us know!
Select the topics that are inaccurate.
Preview not available
Tumor necrosis factor (TNF) plays an essential role in the immunologic maintenance of Mycobacterium tuberculosis infection. Although an increased rate of tuberculosis has been reported in humans treated with anti-TNF biological agents, disparate rates of disease have been observed between those treated with infliximab, an anti-TNF antibody, and etanercept, a TNF-neutralizing TNF receptor (TNFR) fusion molecule. We compared the effects of anti-TNF antibody and soluble TNFR fusion molecule in the murine model of tuberculosis. Systemic TNF neutralization was equivalent between these molecules, and both resulted in rapid morbidity at the initiation of infection. During chronic infection, administration of the receptor fusion molecule allowed the control of infection, whereas antibody treatment caused mice to die within a month. We provide evidence of decreased penetration into the granulomas by the receptor fusion molecule, compared with antibody. These findings begin to clarify the mechanistic difference between anti-TNF agents and their role in the exacerbation of tuberculosis.
The Journal of Infectious Diseases © 2007 Oxford University Press